Company Analysis

Protalix BioTherapeutics, Inc. (PLX)

NYSE: PLX · Biological Products, (No Diagnostic Substances) · Hackensack, NJ · filing with the SEC since 1996
Grade5.4
◀ Past 4.9● Present 7.0▶ Future 3.8

Who runs Protalix BioTherapeutics, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Bashan Dror
PRESIDENT AND CEO. First filing Jul 2019, latest Sep 4, 2026, 3 filings in all.
Officers reporting now
3
of 10 people with a filing in the last fifteen months
Directors reporting now
7
18 people on the record since 2007
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Bashan DrorPRESIDENT AND CEOJul 2019Sep 4, 2026none
Naos YaronSr. VP & COOJun 2018Sep 4, 2026none
Mamlok GiladSr. VP and CFOAug 2025Apr 27, 2026none
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Schwartz AharondirectorNov 2014Sep 9, 2026none
Bar-Shalev AmosdirectorJan 2007Sep 4, 20261 · $0.00
Ben Zvi ShmueldirectorJul 2022Sep 4, 2026none
Boudes Pol FdirectorJan 2020Sep 4, 2026none
Elze ChristiandirectorJul 2025Sep 4, 2026none
Forster EliotdirectorSep 2023Sep 4, 2026none
Melincoff Gwen AdirectorJan 2020Sep 4, 2026none
Earlier names on the record11, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton PLX · research, not advice